DK412788A - Farmaceutisk middel til brug ved behandling af uraemi - Google Patents

Farmaceutisk middel til brug ved behandling af uraemi

Info

Publication number
DK412788A
DK412788A DK412788A DK412788A DK412788A DK 412788 A DK412788 A DK 412788A DK 412788 A DK412788 A DK 412788A DK 412788 A DK412788 A DK 412788A DK 412788 A DK412788 A DK 412788A
Authority
DK
Denmark
Prior art keywords
uraemi
treatment
pharmaceutical agent
amino acids
alpha
Prior art date
Application number
DK412788A
Other languages
English (en)
Other versions
DK412788D0 (da
Inventor
Christian Melin
Jean-Marc Bobee
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9353446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK412788(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthelabo filed Critical Synthelabo
Publication of DK412788D0 publication Critical patent/DK412788D0/da
Publication of DK412788A publication Critical patent/DK412788A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
DK412788A 1987-07-23 1988-07-22 Farmaceutisk middel til brug ved behandling af uraemi DK412788A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8710406A FR2618331B1 (fr) 1987-07-23 1987-07-23 Compositions pharmaceutiques utiles pour le traitement de l'uremie

Publications (2)

Publication Number Publication Date
DK412788D0 DK412788D0 (da) 1988-07-22
DK412788A true DK412788A (da) 1989-01-24

Family

ID=9353446

Family Applications (1)

Application Number Title Priority Date Filing Date
DK412788A DK412788A (da) 1987-07-23 1988-07-22 Farmaceutisk middel til brug ved behandling af uraemi

Country Status (14)

Country Link
US (1) US4908214A (da)
EP (1) EP0300878B1 (da)
JP (1) JPS6434916A (da)
KR (1) KR890001535A (da)
AT (1) ATE69164T1 (da)
AU (1) AU599255B2 (da)
CA (1) CA1329773C (da)
DE (1) DE3866045D1 (da)
DK (1) DK412788A (da)
FR (1) FR2618331B1 (da)
NO (1) NO883261L (da)
NZ (1) NZ225526A (da)
PT (1) PT88086A (da)
ZA (1) ZA885363B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04159219A (ja) * 1990-10-23 1992-06-02 Otsuka Pharmaceut Factory Inc 腎不全用経口アミノ酸製剤
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE299892T1 (de) * 1994-05-18 2005-08-15 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
DE19721206A1 (de) * 1997-05-21 1998-11-26 Babcock Kraftwerkstech Gmbh Vorrichtung zur Entnahme und Kühlung von Bettasche aus einer Wirbelschichtfeuerung
GB9801363D0 (en) * 1998-01-22 1998-03-18 Danbiosyst Uk Novel dosage form
DE60128215T2 (de) 2000-04-20 2008-01-10 Novartis Ag Beschichtungszusammensetzung zur geschmacksmaskierung
FR2822704B1 (fr) * 2001-03-29 2005-02-18 Chiesi Sa Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
AU2002254525B2 (en) * 2001-04-04 2004-12-23 Critical Therapeutics, Inc. Method for preventing acute renal failure
WO2004078171A1 (ja) * 2003-03-06 2004-09-16 Kyowa Hakko Kogyo Co., Ltd. 吸水性アミノ酸含有錠剤
CA2579576A1 (en) * 2004-09-07 2006-03-16 Orphan Medical, Inc. Improved ghb compositions
WO2012137216A1 (en) * 2011-04-06 2012-10-11 Rpg Life Sciences Limited A novel pharmaceutical formulation of alpha ketoanalogue of amino acids and additional amino acids for treatment of chronic kidney disease and method of preparation thereof
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
KR20200039748A (ko) 2017-08-14 2020-04-16 악셀라 헬스 인크. 간 질환 치료를 위한 아미노산 조성물
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
FR2315916A2 (fr) * 1976-03-23 1977-01-28 Univ Johns Hopkins Melanges therapeutiques comprenant des analogues alpha hydroxy acides d'acides amines essentiels et leur administration a l'homme en vue de l'amelioration de la synthese proteique et la suppression de la formation d'uree
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
JPS60237054A (ja) * 1984-05-10 1985-11-25 Nippon Kayaku Co Ltd アミノ酸の晶析法
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
IT1177384B (it) * 1984-12-12 1987-08-26 Boeehringer Biochemia Robin Sp Prodotti dietetici granulari a base di amminoacidi e procedimento per la loro preparazione
US4752619A (en) * 1985-12-23 1988-06-21 The Johns Hopkins University Nutritional supplement for treatment of uremia

Also Published As

Publication number Publication date
AU599255B2 (en) 1990-07-12
US4908214A (en) 1990-03-13
FR2618331B1 (fr) 1991-10-04
JPS6434916A (en) 1989-02-06
KR890001535A (ko) 1989-03-27
ZA885363B (en) 1989-03-29
NO883261L (no) 1989-01-23
DK412788D0 (da) 1988-07-22
NO883261D0 (no) 1988-07-22
CA1329773C (fr) 1994-05-24
DE3866045D1 (de) 1991-12-12
EP0300878B1 (fr) 1991-11-06
EP0300878A1 (fr) 1989-01-25
FR2618331A1 (fr) 1989-01-27
ATE69164T1 (de) 1991-11-15
AU1971988A (en) 1989-01-27
PT88086A (pt) 1989-06-30
NZ225526A (en) 1990-06-26

Similar Documents

Publication Publication Date Title
DK412788D0 (da) Farmaceutisk middel til brug ved behandling af uraemi
FI963424A (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
LU90192I2 (fr) Desirudine et ses sels et dérivés pharmaceutiquement acceptables (revasc)
NL194748B (nl) Osmotische doseringsvorm voor behandeling van cardiovasculaire ziekten.
ES511433A0 (es) "procedimiento de preparacion de productos utiles particularmente en medicamentos utilizables para el tratamiento de melanomas".
ATE23110T1 (de) Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung.
IE900098L (en) The use of the active substance azelastine in combatting¹psoriasis disorders and inflammatory disorders
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
ES2054089T3 (es) Formulaciones orales liquidas.
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
IL95849A0 (en) Pharmaceutical combination containing acetylsalicylic acid and carbacyclin derivatives
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
DK632388A (da) Pharmaceutisk middel til behandling af hyperlipidaemi hol pattedyr
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
GR77250B (da)
AU8744691A (en) N-((2-thenoylmercapto-3-methyl)-butanoyl)-homocysteine thiolactone, a process for the preparation thereof and pharmaceutical compositions containing it
SE8702227D0 (sv) New use
DK39891A (da) N-(2-aminoethyl)-pyridin-2-carboxamid og farmaceutisk anvendelige syreadditionssalte deraf til anvendelse som terapeutisk virksomme stoffer samt laegemidler indeholdende disse forbindelser
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
IT8422685A0 (it) Composizione farmaceutica eprocedimento per il trattamento di eccetazione psicomotoria.
ITMI931174A0 (it) Composizioni farmaceutiche per la cura della talassemia
IT1142260B (it) L-alanina come agente farmaceutico impiegato per la cura di cerebropatie vascolari e relative formulazioni
IT1255380B (it) Nitrobenzoilalanine,procedimento per la loro preparazione,loro uso come agenti terapeutici e composizioni farmaceutiche che le contengono

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment